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SUMMARY – Due to progressive dyspnea, a male patient aged 59 underwent medical exami-
nation in 2003 in a local hospital. Neck ultrasound and fine-needle aspiration biopsy (FNAB) of a 
suspect lesion in the thyroid gland revealed the presence of a malignant neoplasm, i.e. mesenchy-
mal tumor. Immunocytochemistry for epithelial membrane antigen, chromogranin A and leukocyte 
common antigen (CD45) was negative, while vimentin and S-100 were positive. The patient was 
referred to a university hospital center, where further oncologic work-up was done. Neck ultrasound 
revealed a tumor in the left lobe of the thyroid, with extension to the aortic arch. After repeated 
FNAB, cytologic diagnosis of primary thyroid fibrosarcoma was established. Due to the locally 
advanced and consequently inoperable disease, primary radiotherapy to the neck region (64 Gy in 
32 fractions) was applied, followed by 6 cycles of chemotherapy with doxorubicin. After completion 
of therapy, computed tomography scan demonstrated significant regression of primary disease, but 
it was still not amenable to surgical treatment. Thus, the decision of the oncology board was active 
surveillance of the patient. During 9-year follow up, no signs of progression or activity of the disease 
were found.
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Introduction
Fibrosarcoma is a malignant tumor of mesenchy-
mal cell origin derived from fibrous connective tissue, 
composed of malignant fibroblasts in a collagen back-
ground. It is a rare tumor, accounting for 1%-3% of 
all human sarcomas. Nowadays, it is diagnosed less 
frequently, since it can be more reliably distinguished 
histopathologically from similar lesions, such as des-
moid tumors and malignant fibrous histiocytoma. 
Primary fibrosarcoma of thyroid gland is exceptional-
ly rare1, and only few case reports of this type of tumor 
have been reported in the world2–8. Until now, there 
are no known etiologic factors associated with the 
disease. Most commonly, deep soft tissue of lower ex-
tremities (especially thighs and knees) is affected, but 
it can also develop in upper extremities, chest, head, 
neck, as well as in other parts of the body (breast, lung 
and central nervous system). Soft tissue fibrosarcoma 
usually affects patients of a wider age spectrum than 
fibrosarcoma of the bone does, and can occur at any 
age, with the peak incidence between age 30 and 55. 
Although it can develop in the areas of previously 
damaged skin (burns, trauma, chemicals, radiothera-
py, etc.), it usually arises from unchanged normal tis-
sue (de novo). The tumor may present different degrees 
of differentiation: low grade (differentiated), interme-
diate malignancy and high malignancy (anaplastic). It 
is generally a large, painless mass deep to fascia and 
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has an ill-defined margin. Outcome of patients with 
soft tissue fibrosarcoma depends on many interrelated 
factors, among them the size and location of the tu-
mor, histologic grade, and stage of the disease9.
Case Report
A 59-year-old male patient was hospitalized due 
to progressive dyspnea in a local hospital in March 
2003, where thyroid ultrasound (US) and subsequent 
fine-needle aspiration biopsy (FNAB) showed the ex-
istence of a malignant neoplasm, i.e. mesenchymal tu-
mor. Immunocytochemistry for epithelial membrane 
antigen, chromogranin A and leukocyte common an-
tigen (CD45) was negative, while vimentin and S-100 
were positive. 
In July 2003, the patient was referred to a univer-
sity hospital center. Physical examination revealed 
a large palpable mass in the left lobe of the thyroid. 
To evaluate the stage of the disease, neck ultrasound 
(US) and chest and neck computed tomography (CT) 
were done. A locally advanced process was found in 
the left lobe of the thyroid, extending up to the aor-
tic arch, 3.5 cm above the tracheal bifurcation. The 
described tumor measured 82 mm in cranio-caudal 
and 76 mm in latero-lateral diameter (Fig. 1). The pa-
tient underwent US-guided FNAB. Cytologic smears 
were air dried and May-Grünwald-Giemsa stained. 
The smears were normocellular and consisted of loose 
bundles of spindle-shaped cells with fusiform nuclei 
and elongated, poorly delimited cytoplasm (Fig. 2). 
On the basis of morphological and previously known 
immunocytochemistry features, FNAB diagnosis of 
fibrosarcoma was confirmed. Based on the opinions 
of an otorhinolaryngologist and a thoracic surgeon, 
the disease was inoperable, and the conclusion of the 
oncology board was to treat the patient with sequen-
tial radiochemotherapy. Total tumor dose of 64 Gy 
in 32 fractions was applied, with a short break due 
to the development of grade 3 radiodermatitis. After 
radiotherapy, 6 cycles of chemotherapy with doxoru-
bicin were applied (after the first cycle, the dose was 
Fig. 1. Chest and neck CT scan before treatment, July 2003: 
locally advanced process in the left lobe of the thyroid, ex-
tending up to the aortic arch, 82 mm in cranio-caudal and 
76 mm in latero-lateral diameter (white arrows). Trachea 
was shifted to the right, with narrowed lumen in latero-
lateral direction (black arrows).
Fig. 2. Cytologic smear of primary fibrosarcoma of the thy-
roid: the smears were normocellular and consisted of loose 
bundles of spindle-shaped cells with fusiform nuclei and 
elongated, poorly delimited cytoplasm. (May-Grünwald-
Giemsa x MP, and x HP, respectively)
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reduced by 30% due to the development of febrile 
neutropenia). Chemotherapy was completed in Feb-
ruary 2004. 
After completion of chemotherapy, significant re-
gression of the expansive lesion in the left lobe of the 
thyroid was recorded (the tumor measured 4.2 cm on 
CT scan), with no evidence of enlarged lymph nodes 
in the mediastinum (Fig. 3). However, it was still not 
amenable to surgical treatment due to the proximity 
of vital structures. Follow up head and neck CT in 
October 2005 demonstrated an inhomogeneous in-
filtrative process located in the left paratracheal and 
retrotracheal space. The tumor spread from the lower 
half of the left lobe of the thyroid, with cranio-caudal 
diameter of about 6 cm, antero-posterior 3 -3.5 cm and 
latero-lateral up to 4 cm. Part of the esophagus was 
surrounded by the tumor, and the trachea was shifted 
to the right, with narrowed lumen in latero-lateral 
direction.  Last CT scan in September 2009 demon-
strated no signs of disease progression. The process 
was still located in the base of the neck and trachea, 
with the largest diameter of 5.5 cm, reaching out to 
the edges of the vertebrae.
The patient underwent regular follow ups, the last 
one in October 2014, and until now no signs of pro-
gression or dissemination of the disease were record-
ed, so there was no indication for further oncologic 
treatment. The patient felt subjectively well through-
out the follow up period and reported no symptoms 
other than mild swallowing difficulties.
Discussion
Besides fibrosarcoma, all other types of sarcoma 
can be found in the thyroid gland, including lipos-
arcoma, leiomyosarcoma, chondrosarcoma, osteo-
sarcoma and malignant schwannoma1. They all are 
extremely rare and are only sporadically reported10,11. 
Because of its extremely rare incidence, fibrosarcoma 
has not yet been included in the TNM classification 
of thyroid tumors.
Since radiological signs are not specific, the only 
way to diagnose primary thyroid fibrosarcoma is with 
the help of a cytologist or pathologist. It has to be 
noted that cytologic finding may sometimes be in-
conclusive, and can fail to make the correct diagno-
sis. In that case, histopathologic diagnosis by taking 
the sample of the tumor tissue is mandatory. Our pa-
tient underwent FNAB twice, first at a local hospital, 
where the cytologist reported mesenchymal tumor, 
but no further analysis could be done to determine the 
tumor subtype. Some recent studies have shown that 
repeat thyroid FNAB is useful in most cases of pri-
mary indeterminate FNAB findings12. Thus, FNAB 
was later repeated during work-up in our department, 
when upon morphological and previously known im-
munocytochemistry characteristics, the diagnosis of 
fibrosarcoma was made. Since the result was clear, 
histopathologic confirmation of the diagnosis was not 
required.
The natural course of the disease is not characteris-
tic either, with some authors reporting slow-growing 
tumors, and other rapid course of the disease4. The 
patient underwent primary radiotherapy and chemo-
therapy, since the locally advanced disease was found 
during work-up. After primary therapy, the tumor was 
still not amenable to surgical resection and the patient 
was followed-up regularly every 6 months. No signs of 
progression of the disease or of distant metastasis have 
been found to date, so it is evident that our patient is 
fortunately in the group of slow-growing thyroid fib-
rosarcoma. Considering the fact that the tumor was 
inoperable initially, and even after radio- and chemo-
therapy, and later on no progression of the disease was 
found, it is clear that thyroid fibrosarcomas are a very 
unpredictable group of tumors, and it is still (due to 
Fig. 3. Chest and neck CT scan after radiotherapy and 
chemotherapy, March 2004: significant regression of the 
tumor, 4.2 cm in diameter (white arrows). Part of the 
esophagus is surrounded by the tumor (black arrows), and 
the trachea was still shifted to the right.
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a small number of reported cases) not possible to de-
scribe precisely their behavior and prognosis. Despite 
the fact that in our patient, no activity of the disease 
was found in the last 9 years, the decision of our on-
cology board was to continue regular follow up.
Thyroid function was assessed at every patient 
visit; tests included thyroid-stimulating hormone, 
thyroxine/free thyroxine and triiodothyronine/free 
triiodothyronine. Despite the large tumor mass that 
caused atrophic changes by tissue pressure, the patient 
has remained euthyroid to date.
Standard guidelines for the treatment of thyroid 
fibrosarcoma are, considering the small number of 
reported cases, not available. General agreement is 
that surgical treatment with adequate margins is the 
mainstay of treatment. The role of radiotherapy and 
chemotherapy is not clear. Radiotherapy is usually 
applied postoperatively in case of inadequate surgical 
resection, while chemotherapy is an option in high-
grade tumors (as adjuvant therapy), as well as for inop-
erable (as it was in our case) or metastatic disease.
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Sažetak
PRIMARNI FIBROSARKOM ŠTITNE ŽLIJEZDE: PRIKAZ SLUČAJA
N. Dabelić, N. Mateša, T. Jukić, Ž. Soldić, D. Kust, A. Prgomet, A. Bolanča i Z. Kusić
Bolesnik u dobi od 59 godina pregledan je zbog progresivne dispneje u lokalnoj bolnici. Ultrazvukom vrata te citološ-
kom punkcijom suspektne lezije u štitnjači registrirana je maligna neoplazma, tj. mezenhimni tumor. Imunohistokemija 
je bila negativna na antigen epitelnih membrana, kromogranin A i CD45 te pozitivna na vimentin i S-100. Bolesnik je 
upućen u klinički bolnički centar, gdje je provedena daljnja onkološka obrada. Ultrazvukom vrata nađen je tumorski proces 
lijevoga režnja štitnjače sa širenjem na luk aorte. Nakon ponovljene citološke punkcije postavljena je dijagnoza primarnog 
fibrosarkoma štitnjače. Zbog lokalno uznapredovale i posljedično inoperabilne bolesti provedena je primarna radioterapija 
regije vrata (64 Gy u 32 frakcije), nakon čega je bolesnik primio 6 ciklusa kemoterapije doksorubicinom. Nakon završetka 
liječenja kontrolni CT pokazao je značajnu regresiju primarne bolesti koja je, međutim, i dalje bila inoperabilna. S obzirom 
na navedeno, odluka onkološkog konzilija bila je daljnje aktivno praćenje bolesnika. Tijekom 9 godina praćenja u bolesnika 
nisu nađeni znakovi progresije niti aktivnosti bolesti.
Ključne riječi: Fibrosarkom – radioterapija; Fibrosarkom – farmakoterapija; Tiroidni tumori – radioterapija; Tiroidni tumori 
- farmakoterapija
